Wird geladen...
PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?
Rosiglitazone is a synthetic agonist of peroxisome proliferator-activated receptor γ which is used to improve insulin resistance in patients with type II diabetes. Rosiglitazone exerts its glucose-lowering effects by improving insulin sensitivity. Data from various studies in the past decade suggest...
Gespeichert in:
| Hauptverfasser: | , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Baishideng Publishing Group Co., Limited
2011
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3110903/ https://ncbi.nlm.nih.gov/pubmed/21666815 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4330/wjc.v3.i5.144 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|